This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2018
ESMO 2018 Kidney Cancer
ESMO 2018
Press Releases
Kidney Cancer
Prostate Cancer
Bladder Cancer
Conferences
Viewing 61-80 of 10957 articles
ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy
ASCO GU 2024: Baseline Characteristics of Patients with PSMA-PET–positive and –Negative Disease with High-Risk of BCR After RP in the Ongoing Phase 3 PRIMORDIUM Study
ASCO GU 2024: Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC
ASCO GU 2024: Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer
ASCO GU 2024: Low- and High- Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study
ASCO GU 2024: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer: Updated Results
ASCO GU 2024: RC48-ADC Versus BCG in Adjuvant Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer with HER2 Over-Expression: A Real-World Retrospective Study
ASCO GU 2024: Patient Reported Outcomes Among Patients with mCRPC by HRR Mutations Gene Clusters: Findings from the Phase 3 TALAPRO-2 Study Cohort 2
ASCO GU 2024: Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience
ASCO GU 2024: Patient-Reported Outcomes in Patients with BRCA1/2-Altered mCRPC Receiving Niraparib with Abiraterone Acetate and Prednisone: Results from MAGNITUDE Study
ASCO GU 2024: Patient-Reported Outcomes with Talazoparib + Enzalutamide vs. Placebo + Enzalutamide in Men with mCRPC: Subgroup Analysis of Patients with Novel Hormonal Therapy Pretreatment in the TALAPRO-2 Study
ASCO GU 2024: Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC
ASCO GU 2024: Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in mCRPC
ASCO GU 2024: Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD-1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations
ASCO GU 2024: OASIS: Survival Outcomes of Apalutamide as a Starting Treatment - Impact in Real-World Patients with mCSPC
ASCO GU 2024: ProstACT GLOBAL: A Phase 3 Study of Best Standard of Care with and without 177Lu-DOTA-rosopatamab (TLX591) for Patients with PSMA Expressing mCRPC Progressing Despite Prior Treatment with a Novel Androgen Axis Drug
ASCO GU 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec
ASCO GU 2024: Real-world Comparison of PSA Response in Patients with mCSPC Treated with Apalutamide or Enzalutamide
ASCO GU 2024: 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC
ASCO GU 2024: ProstAct-SELECT: Safety, Tolerability, and Dosimetry of 177Lu-TLX591 with Best Standard of Care in Patients with PSMA-Expressing mCRPC
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free